Cancer Genetics, Inc. (NasdaqCM:CGIX) is continuing to evaluate potential strategic options including collaborations, mergers or acquisitions, or other strategic transactions. The Company’s management and Board of Directors are committed to evaluating all potential strategic opportunities and to pursuing the path most likely to create both near and longer-term value for Cancer Genetics’ shareholders. We look forward to keeping shareholders apprised of our progress,” Chief Executive Officer John A. Roberts, concluded.